nab-sirolimus + mFOLFOX6 + bevacizumab

**nab-sirolimus + mFOLFOX6 + bevacizumab** is an experimental combination regimen for cancer treatment, most commonly investigated in advanced or refractory solid tumors, especially colorectal cancer. - **nab-sirolimus** (ABI-009) is an albumin-bound nanoparticle formulation of **sirolimus**, an mTOR inhibitor, designed for improved tissue penetration and antitumor activity. - **mFOLFOX6** is a modified FOLFOX6 regimen, which combines oxaliplatin (a platinum-based cytotoxic chemotherapy), 5-fluorouracil (a pyrimidine analogue antimetabolite), and leucovorin (folinic acid, a biomodulator enhancing 5-FU activity) given in a specific dosing schedule for enhanced efficacy and tolerability[1][2][4][5]. - **bevacizumab** is a humanized monoclonal antibody targeting VEGF-A, thereby inhibiting angiogenesis and blood supply to tumors. This combination leverages the cytotoxic activity of mFOLFOX6, the antiangiogenic action of bevacizumab, and the mTOR pathway inhibition of nab-sirolimus, aiming for enhanced anticancer efficacy via synergistic mechanisms.

Brand names

Abraxane-sirolimus (not a marketed name but following nab-paclitaxel convention)Eloxatin (for oxaliplatin, as part of mFOLFOX6)Avastin (for bevacizumab)

Other names

albumin-bound sirolimus plus modified FOLFOX6 plus bevacizumabnab-rapamycin plus mFOLFOX6 plus bevacizumab